Status:
NOT_YET_RECRUITING
Safety and Efficacy Evaluation of Next-generation CD19-UCART
Lead Sponsor:
Bioray Laboratories
Collaborating Sponsors:
The First Affiliated Hospital of Zhengzhou University
Conditions:
Acute Lymphoblastic Leukemia
Non Hodgkin Lymphoma
Eligibility:
All Genders
1-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Next-generation CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
Detailed Description
CD19-UCART is a kind of "off-the-shelf" product originated from health donor's PBMC. This is an open-label, single arm study to evaluate the safety and anti- tumor efficacy of Next-generation CD19-UCA...
Eligibility Criteria
Inclusion
- Voluntary to participate in this clinical study and sign informed consent form;
- The expected survival period is at least three months;
- There is no other severe cardiopulmonary disease, and the liver and kidney function are normal (except for the subject with tumor lesions in the liver and kidney);
- Patients cannot benefit from autologous CAR-T cell therapy due to T cell separation failure or CART amplification failure in the preparation of autologous CART, or the failure to complete apheresis or disease progression; Or the content of T cells in PBMC of peripheral blood is less than or equal to 10%; Or the disease is not effectively controlled within one month after autologous CAR-T transfusion, and the patient cannot receive CAR-T transfusion again;
- The test results show that CD19 is positive in the tumor;
- Patients with relapsed or refractory CD19-positive acute B-lymphocyte leukemia or B-cell non-Hodgkin's lymphoma. Patients with r/r B-ALL: 1 years old ≤ patient age ≤60 years. Patients with r/r B-NHL: 18 years old ≤ patient age ≤65 years old
- Hematological indicators meet the following conditions: 1) WBC count ≥ 1.5× 10\^9/L; 2) Absolute value of neutrophils ≥ 0.8× 10\^9/L; 3) Lymphocyte count ≥ 0.1× 10\^9/L; 4) Hemoglobin ≥ 60 g/L; 5) Platelet count ≥ 20× 10\^9/L;
- Blood biochemistry shall meet the following requirements 1) or 2): 1) patients with liver and kidney without tumor lesions: A) Total bilirubin (TBIL)≤1.5\*ULN (upper limit of normal value), unless suffering from Gilbert's syndrome; B) aspartate aminotransferase (AST) ≤ 1.5 \* ULN; C) ALT ≤ 1.5 \* ULN; D) Scr ≤ 1.5 \* ULN; E) Urea (URA) ≤ 1.5 \* ULN; 2) patients with liver and kidney tumor lesions: a) TBIL≤5\*ULN； b) AST≤5\*ULN； c) ALT≤5\*ULN； d) SCr≤5\*ULN； e) Urea≤5\*ULN；
- Heart function: good hemodynamic stability, and the left ventricular ejection fraction (LVEF) is higher than or equal to 55%;
- Serum viruses such as HIV, TP, HBV(HBV-DNA) and HCV(HCV-DNA) are all negative;
- ECOG activity status score: 0-2 points;
- Accept the requirement that effective contraception be used throughout the study;
- Willing to abide by the rules established in this study.
Exclusion
- Pregnant or lactating women;
- Having a pregnancy plan in the next two years;
- Has received graft-versus-host disease treatment in the past;
- Has received allogeneic cell therapy in the past 6 weeks;
- Has received allogeneic stem cell transplantation within the past 6 months;
- Individual extramedullary relapse B-ALL;
- Suffering from severe mental disorder;
- Active autoimmune diseases requiring immunotherapy;
- Has suffered from other malignant tumors in the past;
- Patients with severe cardiovascular disease;
- Prothrombin time or activated partial thromboplastin time or international normalized ratio \> \>1.5\*ULN； in the absence of anticoagulant therapy;
- There is active infectious disease or need any major infection events of high-level antibiotics; 13. Any condition that, in the opinion of the investigator, may increase the subject's risk or interfere with the study results.
Key Trial Info
Start Date :
December 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 3 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05381181
Start Date
December 20 2023
End Date
May 3 2026
Last Update
January 27 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.